FDA MedWatch - Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer - Drugs.com MedNews
Links shared publicly online about this topic.
- 130total visits
FDA MedWatch - Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer - Drugs.com MedNews
Includes Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludrona
View full resource at drugs.com
Tags: Digestion, Esophageal Cancer, Osteoporosis, Osteoporosis Medication, Drug, FDA, Safety
Most Recently Shared on July 21, 2011 at 8:33 pm By:
FDA MedWatch - Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased ... http://bit.ly/o1R3F8 #drug
Advertisement
